Haemonetics Corporation (NYSE:HAE) shares jumped 16.3% on Tuesday following the company’s announcement of a non‑exclusive supply agreement with CSL Plasma Inc. The agreement, signed on August 14, 2026, permits CSL to utilize Haemonetics’ NexSys PCS devices equipped with Persona PLUS technology and to purchase related disposables for use in the United States. No minimum purchase commitments are included in the contract. CSL is expected to transition a portion of its U.S. plasma collection centers to Haemonetics’ devices and disposables, although the exact scope and timing of this rollout have not yet been determined. Haemonetics indicated that it will not revise its previously issued fiscal 2027 guidance at this time because of the uncertainty surrounding implementation details. The company plans to provide an update on the anticipated impact of the agreement on its fiscal 2027 financial results during its second‑quarter earnings call scheduled for November 2026. While the supply agreement represents a potential expansion opportunity in the plasma collection market, the financial impact remains unclear pending further details on CSL’s deployment plans.